AstraZeneca and Daiichi Sankyo's breast cancer medicine was not recommended for about 1,000 extra patients in England by the drug-price regulator due to cost concerns. Efforts to make Enhertu available on the NHS in England failed after no price agreement was reached with the manufacturer, leading to outrage as breast cancer patients are denied access to the life-extending drug in England, prompting some to consider moving to Scotland where the drug is available on the NHS.
⚠️ GROUP SUING OVER PFIZER DIVERSITY FELLOWSHIP PROGRAM LOSES US APPEAL Full Story → https://t.co/vVzq6iFRZD A U.S. appeals court on Wednesday upheld the dismissal of a lawsuit by a conservative group opposed to diversity initiatives in medicine that challenged a Pfizer… https://t.co/tybiqgop4i
NHS watchdog blocks breast cancer drug in England via @FT $AZN https://t.co/eXO8IlliVc
Breast cancer patients in England may be forced to move to Scotland to get a life-saving drug on the NHS after its use on the health service was blocked south of the border @PMGallagher1 reports https://t.co/CalHUlO94H
Outrage as thousands of breast cancer-stricken women in England are denied life-extending drug available in Scotland https://t.co/TeXJ1dZlbJ https://t.co/VSGSKyLo1u
Breast Cancer Drug Won’t Be Offered to 1,000 Patients in England https://t.co/sDrvyBvwhN
England’s drug-price regulator won’t recommend AstraZeneca and Daiichi Sankyo’s breast cancer medicine for about 1,000 extra patients, on the grounds that it isn’t cost effective https://t.co/9t4VFjWBwD
Enhertu will not be made available on the NHS in England after commercial talks with its manufacturer ended with no price agreement in place (via @PA) https://t.co/ykD5ZB82Fi
NHS watchdog blocks breast cancer drug in England https://t.co/PYzbbwqysS
AstraZeneca’s drug pricing lawsuit dismissed by federal judge https://t.co/dhTG88Wefn $AZN @ByJonGardner